DexCom (DXCM) shares are still under investigation by Johnson Fistel, with Goldman Sachs initiating coverage for the company with a buy recommendation. The company's
Q1 earnings reportedly missed estimates, despite exceeding Q1 expectations. This initiates a bullish sentiment for the company's stock. Recent growth has led to DexCom's stock being a leader among S&P 500 gainers, with the consensus of stock analysts pointing to a potential upside of 13.59%.
New leadership changes have put Jake Leach in the president role, gaining the company positive coverage. Citi raised their price target to $102. Strategic partnerships have been announced. The company reported encouraging financial results for Q1, 2025, including a $750 million share repurchase program.The company's new wearable glucose management system, DexCom G7 15 Day, recently received FDA clearance, making it the longest lasting wearable and most accurate CGM system. Future prospects include attending an upcoming conference presentation and launching products in the U.S.Risks identified include an issued FDA warning letter to DexCom and a slight slow in revenue growth. However, a potential recovery might be in sight following a Q4 stumble.
Dexcom DXCM News Analytics from Mon, 23 Sep 2024 07:00:00 GMT to Tue, 10 Jun 2025 18:06:00 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor 0
